Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Net Cash Flow: 2023-2025

Historic Net Cash Flow for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $128.8 million.

  • Immunome's Net Cash Flow rose 1418.75% to $128.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.2 million, marking a year-over-year increase of 80.48%. This contributed to the annual value of $44.7 million for FY2024, which is 42.99% down from last year.
  • Latest data reveals that Immunome reported Net Cash Flow of $128.8 million as of Q3 2025, which was up 213.32% from -$113.6 million recorded in Q2 2025.
  • Immunome's Net Cash Flow's 5-year high stood at $171.0 million during Q1 2024, with a 5-year trough of -$113.6 million in Q2 2025.
  • Over the past 3 years, Immunome's median Net Cash Flow value was $8.0 million (recorded in 2023), while the average stood at $22.9 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 1,637.53% in 2024, then surged by 1,418.75% in 2025.
  • Immunome's Net Cash Flow (Quarterly) stood at $8.0 million in 2023, then tumbled by 251.99% to -$12.2 million in 2024, then soared by 1,418.75% to $128.8 million in 2025.
  • Its Net Cash Flow stands at $128.8 million for Q3 2025, versus -$113.6 million for Q2 2025 and $114.3 million for Q1 2025.